PT - JOURNAL ARTICLE AU - J. Mur AU - S. R. Cox AU - R. E. Marioni AU - G. Muniz-Terrera AU - T. C. Russ TI - Increase in anticholinergic burden in the UK from 1990 to 2015: a UK Biobank study AID - 10.1101/2020.10.16.20213884 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.16.20213884 4099 - http://medrxiv.org/content/early/2020/10/18/2020.10.16.20213884.short 4100 - http://medrxiv.org/content/early/2020/10/18/2020.10.16.20213884.full AB - Background The use of prescription drugs with anticholinergic properties has been associated with multiple negative health outcomes in older people. Moreover, recent evidence suggests that associated adverse effects may occur even decades after stopping anticholinergic use. Despite the implicated importance of examining longitudinal patterns of anticholinergic prescribing for different age groups, few such data are available.Methods We performed an age-period-cohort analysis to study trends in anticholinergic burden between the years 1990 and 2015 utilising data from >220,000 UK Biobank participants with linked prescription data from primary care.Results Anticholinergic burden in the sample increased between three- and nine-fold over 25 years and was significant for both period/cohort- and age-effects across all models. When adjusted for total number of prescriptions, the effect of age reversed. Anticholinergic burden was also associated with various lifestyle- and demographic factors.Conclusions The increase in anticholinergic prescribing is mostly due to an increase in polypharmacy and is attributable to both ageing of participants, as well as period/cohort-related changes in prescribing practices. There is evidence for deprescribing of anticholinergic medications in older age. Further research is needed to clarify the implications of rising anticholinergic use for public health and to contextualise this rise in light of other relevant prescribing practices.Competing Interest StatementThe authors have declared no competing interest.Funding StatementREM is supported by Alzheimer's Research UK major project grant ARUK‐PG2017B‐10. JM is supported by funding from the Wellcome Trust 4‐year PhD in Translational Neuroscience-training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z]. JM and TCR are members of the Alzheimer Scotland Dementia Research Centre funded by Alzheimer Scotland. TCR is employed by NHS Lothian and the Scottish Government. SRC is supported by Age UK (Disconnected Mind project), the UK Medical Research Council [MR/R024065/1] and a National Institutes of Health (NIH) research grant R01AG054628.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee (REC) (reference 11/NW/0382).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data is available via UK Biobank. https://github.com/Logos24/Anticholinergic-trends-UK-Biobank